Williams C J, Barley V L, Blackledge G R, Rowland C G, Tyrrell C J
Royal South Hants Hospital, Southampton, UK.
Br J Cancer. 1993 Dec;68(6):1210-5. doi: 10.1038/bjc.1993.506.
Trilostane and Aminoglutethimide, each given with a physiological replacement dose of hydrocortisone, were randomly allocated to 72 eligible postmenopausal advanced breast cancer patients; following treatment failure on either drug the patient continued with the other drug, if in a suitable clinical condition. Thirty-eight patients initially received Trilostane of whom 19 subsequently received Aminoglutethimide; 34 patients initially had Aminoglutethimide and seven of these then received Trilostane. Both groups of patients were comparable in all respects. There was no difference in the objective response rate to either drug, Trilostane 11/38 = 29%, Aminoglutethimide 12/34 = 35%, nor in the average time to disease progression for the two drugs, Trilostane 64 weeks, Aminoglutethimide 68 weeks. Of the 26 patients who received both drugs, four showed a response to both suggesting no cross resistance. Side effects were seen to both drugs in approximately half of the patients, but were mainly gastro-intestinal with Trilostane and rash and drowsiness with Aminoglutethimide. There was no evidence of cross over patient susceptibility to side effects.
曲洛司坦和氨鲁米特分别与生理替代剂量的氢化可的松联合使用，被随机分配给72名符合条件的绝经后晚期乳腺癌患者；如果患者处于合适的临床状态，在任何一种药物治疗失败后，继续使用另一种药物。38名患者最初接受曲洛司坦治疗，其中19名随后接受氨鲁米特治疗；34名患者最初接受氨鲁米特治疗，其中7名随后接受曲洛司坦治疗。两组患者在各方面均具有可比性。两种药物的客观缓解率没有差异，曲洛司坦为11/38 = 29%，氨鲁米特为12/34 = 35%，两种药物的疾病进展平均时间也没有差异，曲洛司坦为64周，氨鲁米特为68周。在接受两种药物治疗的26名患者中，有4名对两种药物均有反应，表明不存在交叉耐药性。大约一半的患者出现了两种药物的副作用，但曲洛司坦的副作用主要是胃肠道反应，氨鲁米特的副作用是皮疹和嗜睡。没有证据表明患者对副作用存在交叉易感性。
